Skip to main content
SEOUL PHARMA CO.,LTD logo

SEOUL PHARMA CO.,LTD — Investor Relations & Filings

Ticker · 018680 ISIN · KR7018680009 KO Manufacturing
Open in API
Filings indexed 150 across all filing types
Latest filing 2026-04-01 Major Shareholding Noti…
Country KR South Korea
Listing KO 018680

About SEOUL PHARMA CO.,LTD

http://www.seoulpharmaceuticals.com/

Seoul Pharma Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of pharmaceutical products. The company specializes in innovative drug delivery systems, with a core competency in Orally Disintegrating Film (ODF) technology. Its product portfolio includes a wide range of prescription and over-the-counter medications. Key therapeutic areas cover cardiovascular and respiratory systems, as well as anti-infective agents such as antibacterials, antifungals, and antivirals. The company also produces vitamins and antibiotics, aiming to improve health outcomes through its cutting-edge technological capabilities.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a statutory “주식등의 대량보유상황보고서(일반)” (Report on Large Shareholdings) filed under Korea’s Capital Markets Act. It details the number of shares and voting rights held by a major investor (a private equity fund and its affiliates), including changes during the reporting period. This matches the definition of a Major Shareholding Notification – reporting significant share ownership levels and threshold crossings.
2026-04-01 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 1% confidence The document is a regulatory notification concerning the appointment, reappointment, and expiration of outside directors (사외이사) at Seoul Pharmaceutical Co., Ltd. It details changes in the board composition, listing dates of appointments and terms, which clearly falls under announcements of changes in the company’s board of directors. This aligns precisely with the "Board/Management Information" category (MANG).
2026-03-27 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a Korean regulatory filing titled “임원ㆍ주요주주 특정증권등 소유상황보고서,” which details an officer’s (신봉환) personal ownership and changes in specific securities of the company (서울제약). It specifies the number of shares held before and after a transaction, acquisition/disposition price, and trading date. This matches the definition of a Director’s Dealing report (insider transactions by executives). Therefore, the correct classification is DIRS.
2026-03-27 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled “정기주주총회결과” (Results of the Annual General Meeting) and details each proposal tabled at the 2026-03-27 AGM, including approval of financial statements, director appointments, and voting percentages. It provides the official voting results of the shareholder meeting. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement.
2026-03-27 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report' (감사보고서) for Seoul Pharma (주식회사 서울제약) for the fiscal year ending December 31, 2025. It includes the independent auditor's report from Samil PricewaterhouseCoopers, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes to the financial statements. This is a comprehensive financial audit document, not an earnings release or a summary report. FY 2025
2026-03-19 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a formal regulatory filing from Seoul Pharma (서울제약) titled 'Submission of Audit Report' (감사보고서 제출). It provides the audit opinion (unqualified/적정), key financial data (assets, liabilities, revenue, profit/loss), and the name of the auditor (Samil PwC). While it contains financial data, it is a standardized regulatory disclosure form used in the Korean market to announce the receipt and submission of the audit report to the exchange, rather than the full annual report document itself. Therefore, it is classified as an Audit Report/Information filing. FY 2025
2026-03-19 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.